Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

BACKGROUND: The effectiveness of regorafenib plus programmed cell death-1 (PD-1) inhibitor in treating microsatellite stable (MSS) metastatic colorectal cancer (mCRC) remains controversial. AIM: To investigate the benefits of regorafenib combined with PD-1 inhibitor in treating MSS mCRC and explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yu-Jie, Zhang, Peng, Hu, Jin-Long, Liang, Hong, Zhu, Yan-Yan, Cui, Yao, Niu, Po, Xu, Min, Liu, Ming-Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048533/
https://www.ncbi.nlm.nih.gov/pubmed/35582108
http://dx.doi.org/10.4251/wjgo.v14.i4.920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048533/
https://www.ncbi.nlm.nih.gov/pubmed/35582108
http://dx.doi.org/10.4251/wjgo.v14.i4.920

Ejemplares similares